Top Medical Companies To Watch In Right Now

Toward the end of trading Tuesday, the Dow traded down 0.32 percent to 15,351.10 while the NASDAQ fell 0.12 percent to 3,780.30. The S&P was also down, dropping 0.18 percent to 1,698.55.

Top Headline
Lennar (NYSE: LEN) reported a 39% rise in its third-quarter net profit. Lennar's quarterly net profit surged to $120.7 million, or $0.54 per share, from $87.1 million, or $0.40 per share, in the year-ago period. Its revenue rose 46% to $1.6 billion from $1.1 billion, while new orders climbed 14%. However, analysts were estimating earnings of $0.45 per share on revenue of $1.55 billion.

Equities Trading UP
Greenway Medical Technologies (NYSE: GWAY) shot up 18.91 percent to $20.37 after the company agreed to be acquired by Vista Equity Partners for $20.35 per share.

Top Chemical Companies To Own For 2015: Johnson & Johnson(JNJ)

Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment provides products used in baby care, skin care, oral care, wound care, and women?s health care fields, as well as nutritional, over-the-counter pharmaceutical products, and wellness and prevention platforms under the brands of JOHNSON?S, AVEENO, CLEAN & CLEAR, JOHNSON?S Adult, NEUTROGENA, RoC, LUBRIDERM, DABAO, LISTERINE, REACH, BAND-AID, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC. The Pharmaceutical segment offers products in various therapeutic areas, such as anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, and virology. Its principal products include REMICADE for the treatment of immune me diated inflammatory diseases; STELARA for the treatment of moderate to severe plaque psoriasis; SIMPONI, a treatment for adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; VELCADE for the treatment of multiple myeloma; PREZISTA and INTELENCE for treating HIV/AIDS patients; NUCYNTA for moderate to severe acute pain; INVEGA SUSTENNAtm for the acute and maintenance treatment of schizophrenia in adults; RISPERDAL CONSTA for the management of bipolar I disorder and schizophrenia; and PROCRIT to stimulate red blood cell production. The Medical Devices and Diagnostics segment primarily offers circulatory disease management products; orthopaedic joint reconstruction, spinal care, and sports medicine products; surgical care, aesthetics, and women?s health products; blood glucose monitoring and insulin delivery products; professional diagnostic products; and disposable contact lenses. The company was founded in 1886 and is based in Ne w Brunswick, New Jersey.

Advisors' Opinion:

• [By Brian Orelli]

  And if doctors don't like any of those choices, there's a new class of drugs called SGLT-2 inhibitors that work though a different mechanism. Johnson & Johnson (NYSE: JNJ  ) got the first one approved earlier this year. Since it's a new class of drugs, doctors are likely to be cautious, but given the choice between unknown real-world experience and Avandia's history, I think most doctors would choose the unknown.

• [By Brian Orelli]

  Pfizer's blood thinner, Eliquis, was approved late last year. The drug, which Pfizer sells with Bristol-Myers Squibb (NYSE: BMY  ) , has multibillion-dollar potential because the current offering, warfarin, is difficult to use. While doctors are clamoring for a replacement, drugmakers developed three. In addition to Eliquis, there's also Johnson & Johnson's (NYSE: JNJ  ) Xarelto and Boehringer Ingelheim's Pradaxa. The blood thinner market is so large, I think there's plenty of room for all three.

• [By Dan Carroll]

  Merck's diabetes drug pair, Januvia and Janumet, paid off in a big way for investors last year with more than $5.7 billion in sales. However, Januvia's sales dipped surprisingly in the first quarter, and more headaches could be on the way. Johnson & Johnson's (NYSE: JNJ  ) newly approved diabetes treatment, Invokana, has already shown some benefits over Januvia in certain clinical trials and could be poised to take a bite out of Merck's sales. Along with the FDA's investigation into pancreatitis concerns for Januvia patients, Merck's star drug isn't having its best time right now. Any threat to its billions of dollars in sales could drastically hurt this firm's future.

• [By Monica Gerson]

  Breaking news

  Shares of Joy Global (NYSE: JOY) fell more than 2.7% in pre-market trading after the company reported weaker-than-expected third-quarter earnings. To read the full news, click here. Johnson & Johnson (NYSE: JNJ) today announced it will fast-track the development of a promising new combination vaccine regimen against Ebola and broadly collaborate with its partners in global health to deliver immediate relief aid to address the current Ebola outbreak. To read the full news, click here. Shares of Ciena (NYSE: CIEN) dipped more than 12% in pre-market trading after the company issued a weak fiscal fourth-quarter forecast. However, the company reported upbeat third-quarter results. To read the full news, click here. Boeing (NYSE: BA), China's leading provider of passenger airplanes, projects a demand in the country for 6,020 new airplanes over the next 20 years, valued at $870 billion. To read the full news, click here.

  Posted-In: JP Morgan US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

Top Medical Companies To Watch In Right Now: ANI Pharmaceuticals Inc (ANIP)

ANI Pharmaceuticals, Inc., incorporated on April 11, 2001, is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. In two facilities with combined manufacturing, packaging and laboratory capacity totaling 173, 00 square feet, the Company manufactures oral solid dose products, as well as liquids and topicals, including narcotics. Its other products include The Food and Drug Administration (FDA) approved testosterone gel, which is licensed to Teva Pharmaceuticals USA. In December 2013, the Company acquired 31 generic drug products from Teva Pharmaceuticals, which includes 20 solid-oral immediate release products, four extended release products and seven liquid products.

The Company performs contract manufacturing for other pharmaceutical companies. It has launched three products and has 11 products in development. The Company�� targeted areas of product development include narcotics, anti-cancers and hormones (potent compounds), and extended release niche generic product opportunities.

Advisors' Opinion:

• [By Lisa Levin]

  ANI Pharmaceuticals (NASDAQ: ANIP) shares climbed 9.42% to $20.79. The volume of ANI Pharmaceuticals shares traded was 651% higher than normal. ANI Pharmaceuticals shares have jumped 121.45% over the past 52 weeks, while the S&P 500 index has surged 25.37% in the same period.

Top Medical Companies To Watch In Right Now: Foundation Medicine Inc (FMI)

Foundation Medicine, Inc., incorporated on November 12, 2009, is a commercial-stage company. The Company is focused on fundamentally changing the way patients with cancer are treated. The Company�� platform includes methods and algorithms for analyzing tumor tissue samples across all types of cancer, as well as information aggregation and concise reporting capabilities. Its products provide genomic information about each patient�� individual cancer, enabling physicians to optimize treatments in clinical practice and enabling biopharmaceutical companies to develop targeted oncology therapies more effectively.

FoundationOne, its first clinical product, is, to its knowledge, the only commercially available comprehensive molecular information product designed for use in the routine care of patients with cancer. In addition, the Company is considered a non-contracting provider by commercial third-party payors because it has not entered into specific contracts to provide FoundationOne to their covered patients, and as a result it takes on primary responsibility for obtaining reimbursement on behalf of patients.

Advisors' Opinion:

• [By Lisa Levin]

  Foundation Medicine (NASDAQ: FMI) shares tumbled 7.58% to reach a new 52-week low of $21.23. Foundation Medicine's trailing-twelve-month profit margin is -147.08%.

• [By Bryan Murphy]

  Eat your heart out Foundation Medicine Inc. (NASDAQ:FMI). And WebMD Health Corp. (NASDAQ:WBMD)? Don't even bother trying. CollabRx Inc. (NASDAQ:CLRX) has built a better mousetrap, and if yesterday's announcement is a sign of things to come, CLRX could prove to be a very compelling investment.

• [By James E. Brumley]

  It wouldn't be fair to say there's nothing like it "out there", because there is. A company called Foundation Medicine Inc. (NASDAQ:FMI) has developed a similar/comparable app. The CLRX version of the solution appears superior in most ways, however, if for no other reason than because of the projected revenue growth the company is apt to see.

• [By John Udovich]

  Yesterday, small cap biotech Acceleron Pharma Inc (NASDAQ: XLRN) rose 9.76%�plus shares are up 183.6% for retail investors since its September IPO, meaning its worth taking a closer look at the stock along with the performance of other biotech IPOs like BIND Therapeutics Inc (NASDAQ: BIND), Ophthotech Corp (NASDAQ: OPHT) and Foundation Medicine Inc (NASDAQ: FMI) which also debuted at the same time.

Top Medical Companies To Watch In Right Now: Acceleron Pharma Inc (XLRN)

Acceleron Pharma Inc., incorporated on June 13, 2003, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. The Company�� research focuses on the biology of the Transforming Growth Factor-Beta (TGF-b) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body. By coupling its discovery and development expertise, including its knowledge of the TGF-b superfamily, with its internal protein engineering and manufacturing capabilities, it has built a productive research and development platform that has generated clinical and preclinical protein therapeutic candidates with mechanisms of action.

The Company focuses on discovering and developing protein therapeutics that target a group of approximately 30 secreted proteins, or ligands, that are collectively referred to as the TGF-b superfamily. These ligands bind to subsets of 12 different receptors on the surface of cells, triggering intra-cellular changes in gene expression that guide cell growth and differentiation. The TGF-b superfamily ligands and their receptors represent an under-explored and diverse set of drug targets with the potential to yield therapeutics that modulate the growth and repair of diseased cells and tissues.

The Company has three internally discovered protein therapeutic candidates that are being studied in 12 ongoing Phase 2 clinical trials, focused on cancer and rare diseases. The Company�� two advanced protein therapeutic candidates, sotatercept and ACE-536, promote red blood cell production through a novel mechanism. Together with its collaboration partner, Celgene Corporation, the Company is developing sotatercept and ACE-536 to treat anemia and associated complications in patients with b-thalassemia and myelodysplastic syndromes (MDS). These red blood cell disorders are generally unresponsive to approved dru! gs. The Company�� third clinical stage protein therapeutic candidate, dalantercept, is designed to inhibit blood vessel formation through a mechanism that is distinct from, and potentially synergistic with, the dominant class of cancer drugs that inhibit blood vessel formation, the vascular endothelial growth factor (VEGF) pathway inhibitors. The Company is developing dalantercept primarily for use in combination with these products to produce better outcomes for cancer patients.

The Company and Celgene have conducted six human clinical trials with sotatercept in over 160 healthy volunteers and cancer patients. The Company has conducted one clinical trial with ACE-536 in healthy volunteers. In these studies, both sotatercept and ACE-536 caused a dose-dependent increase in the number of red blood cells. Based on these results, the Company and Celgene have initiated Phase II clinical trials with each of these protein therapeutic candidates in b-thalassemia and MDS. In the ongoing trial of sotatercept in patients with b-thalassemia, the Company has observed encouraging, dose-dependent increases in hemoglobin in a subset of patients at the two lowest dose levels.

Sotatercept is a soluble receptor fusion protein consisting of the extracellular domain of the activin receptor type IIA (ActRIIA) linked to the Fc domain of human IgG1. Sotatercept acts as a protein trap for TGF-b superfamily ligands that signal through the ActRIIA receptor. Sotatercept has increased red blood cells in multiple clinical trials. ACE-536 is a soluble receptor fusion protein consisting of a modified extracellular domain of the activin receptor type IIB (ActRIIB) linked to the Fc domain of human IgG1.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Shares of Acceleron Pharma (NASDAQ: XLRN) got a boost, shooting up 16.74 percent to $39.54 after Form 8-K for Acceleron Pharma showed that Celgene (NASDAQ: CELG) will buy 1.1 million shares for $47.15 million.

• [By John Udovich]

  Yesterday, small cap biotech Acceleron Pharma Inc (NASDAQ: XLRN) rose 9.76%�plus shares are up 183.6% for retail investors since its September IPO, meaning its worth taking a closer look at the stock along with the performance of other biotech IPOs like BIND Therapeutics Inc (NASDAQ: BIND), Ophthotech Corp (NASDAQ: OPHT) and Foundation Medicine Inc (NASDAQ: FMI) which also debuted at the same time.

Top Medical Companies To Watch In Right Now: Redpoint Bio Corp (RPBC)

Redpoint Bio Corporation (Redpoint), incorporated in August 1995, is a development-stage biotechnology company. The Company leverages discoveries in the molecular biology of taste to discover and develop taste modulators for the food and beverage industries. Its food and beverage program has been focused on identifying flavor modifiers that improve the taste of ingredients. In June 2009, the Company announced that it had identified an all-natural sweetness enhancer, RP44. RP44 is Reb-C (rebaudioside C), a component of the stevia plant.

Sweetness Enhancer Program

Redpoint announced that it had identified RP44, an all-natural sweetness enhancer, in June 2009. In January 2010, it disclosed that RP44 is Reb-C (rebaudioside C), a component of the stevia plant. RP44 is derived from material found in the side stream of the Reb A production process. A purified component of stevia known as Reb A has received regulatory approval in the United States. Unlike Reb A, RP44 has a low intrinsic level of sweetness and therefore is not useful as a sweetener.

Diabetes and Obesity Drug Discovery Program

The Company�� initial programs focused on the modulation of the TRPm5 ion channel, a signaling element in taste sensation, in order to discover compounds that modulate the taste of food and beverage products. Redpoint initiated a program designed to leverage the research it had already conducted on the discovery of modulators of the TRPm5 ion channel to further explore opportunities for the discovery of diabetes or obesity therapeutics. TRPm5 modulators discovered at Redpoint have been shown to elicit the secretion of hormones known to play roles in metabolism in relevant model systems.

The Company competes with International Flavors & Fragrances Inc., Givaudan SA, Symrise, Firmenich, Senomyx, PureCircle Ltd, GLG Life Tech Corporation, Eli Lilly and Company, Amylin Pharmaceuticals, Merck & Co., Inc., Metabolex, Inc., OSI Pharmaceuticals, GlaxoSmithKline! , Arena Pharmaceuticals, Inc. and Johnson & Johnson.

Advisors' Opinion:

• [By Peter Graham]

  Small cap stocks Greenfield Farms Food Inc (OTCMKTS: GRAS), International Stem Cell Corp (OTCMKTS: ISCO) and Redpoint Bio Corporation (OTCMKTS: RPBC) have all been getting some extra attention lately in various investment newsletters. However, none of these small cap stocks appear to have been the subject or paid promotions or investor relations activities. So does that make any of them good bets for traders and investors alike? Here is a quick look and a reality check:

Top Medical Companies To Watch In Right Now: Cellular Dynamics International Inc (ICEL)

Cellular Dynamics International, Inc., incorporated on November 16, 2007, develops and manufactures fully functioning human cells in industrial quantities to precise specifications. The Company�� iCell Operating System (iCell O/S) includes true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). Customers use its iCell O/S products, among other purposes, for drug discovery and screening; to test the safety and efficacy of their small molecule and biologic drug candidates; for stem cell banking; and in researching cellular therapeutics. The Company�� iCell product line includes four different cell types: cardiomyocytes, neurons, hepatocytes and endothelial cells. The Company is actively developing an additional seven different cell types. iCell products are a consumable designed to be used once and then reordered.

The Company manufactures its iCell products from its iPSCs. An iPSC is a cell that has the ability both to replicate indefinitely and to be transformed into any cell type in the human body. The Company�� iCell O/S consists of six products, which include iCell Cardiomyocytes, iCell Neurons, iCell Endothelial Cells, iCell Hepatocytes and MyCell.

Advisors' Opinion:

• [By John Udovich]

  Stem cells may not be in the news much�as the sector has moved beyond the use of embryotic�ones, but small cap stem cell stocks Cellular Dynamics International Inc (NASDAQ: ICEL), International Stem Cell Corp (OTCMKTS: ISCO) and BioRestorative Therapies (OTCBB: BRTX) have been fairly active over the past several trading days as ICEL went public, ISCO raised additional funding and BRTX grabbed more attention: